RECRUITING

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Conditions

Pancreatic Adenocarcinoma irreversible electroporation Nivolumab

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Compare the efficacy and tolerability of irreversible electroporation in combination with Nivolumab in patients with locally advanced pancreatic cancer.

Official Title

Immunotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Quick Facts

Study Start:2017-08-14

Study Completion:2026-04-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT03080974

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* ≥ 18 years if age * Diagnosed with stage III pancreatic cancer * Tumor is measurable * Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2) * Willing and able to comply with the protocol requirements * Able to comprehend and have signed the informed consent to participate	* Participating in another clinical trial for the treatment of cancer at time of screening * Are pregnant or currently breast feeding * Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure * Have non-removable implants with metal parts within 1 cm of the target lesion * Had a myocardial infarction within 3 months prior to enrollment

Inclusion Criteria

Exclusion Criteria

* ≥ 18 years if age
* Diagnosed with stage III pancreatic cancer
* Tumor is measurable
* Glomerular Filtration Rate \> 60 m/L/min/1.73 m(2)
* Willing and able to comply with the protocol requirements
* Able to comprehend and have signed the informed consent to participate

* Participating in another clinical trial for the treatment of cancer at time of screening
* Are pregnant or currently breast feeding
* Have a cardiac pacemaker or Implantable Cardioverter Defibrillator implanted that cannot be deactivated during the procedure
* Have non-removable implants with metal parts within 1 cm of the target lesion
* Had a myocardial infarction within 3 months prior to enrollment

Contacts and Locations

Study Contact

Marilyn Donaldson, RN

CONTACT

502-629-3323

marilyn.donaldson@louisville.edu

Principal Investigator

Robert Martin, MD, PhD

PRINCIPAL_INVESTIGATOR

University of Louisville

Study Locations (Sites)

University of Louisville

Louisville, Kentucky, 40202

United States

Collaborators and Investigators

Sponsor: University of Louisville

Robert Martin, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Louisville

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2017-08-14

Study Completion Date2026-04-01

Study Record Updates

Study Start Date2017-08-14

Study Completion Date2026-04-01

Terms related to this study

Keywords Provided by Researchers

irreversible electroporation
Nivolumab

Additional Relevant MeSH Terms

Pancreatic Adenocarcinoma